Literature DB >> 26981630

Methotrexate for Inflammatory Bowel Diseases - New Developments.

Hans H Herfarth1.   

Abstract

Methotrexate (MTX) is an established therapy for patients with steroid-dependent Crohn's disease (CD). MTX is also frequently used in combination with anti-TNF agents to suppress anti-drug antibody formation. It has been suggested in the past that MTX lacks any clinical effectiveness in patients with ulcerative colitis (UC); however, newer data at least partially contradict this assumption. The following review will discuss recent data for the use of MTX in CD, UC and in combination with anti-TNF agents.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26981630      PMCID： PMC4820247          DOI： 10.1159/000443129

Source DB:  PubMed          Journal:  Dig Dis        ISSN： 0257-2753            Impact factor:   2.404


  42 in total

Review 1.  Methotrexate for maintenance of remission in Crohn's disease.

Authors:  Vishal Patel; Yongjun Wang; John K MacDonald; John W D McDonald; Nilesh Chande
Journal:  Cochrane Database Syst Rev       Date:  2014-08-26

2.  Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn's disease.

Authors:  Whitney Sunseri; Jeffrey S Hyams; Trudy Lerer; David R Mack; Anne M Griffiths; Anthony R Otley; Joel R Rosh; Ryan Carvalho; Andrew B Grossman; Jose Cabrera; Marian D Pfefferkorn; James Rick; Neal S Leleiko; Meredith C Hitch; Maria Oliva-Hemker; Shehzad A Saeed; Michael Kappelman; James Markowitz; David J Keljo
Journal:  Inflamm Bowel Dis       Date:  2014-08       Impact factor: 5.325

3.  Methotrexate in IBD: the return of the prodigal son.

Authors:  Thibaut Vaysse; Franck Carbonnel
Journal:  J Crohns Colitis       Date:  2015-04       Impact factor: 9.071

Review 4.  Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.

Authors:  Parambir S Dulai; Corey A Siegel; Jean-Frederic Colombel; William J Sandborn; Laurent Peyrin-Biroulet
Journal:  Gut       Date:  2014-06-26       Impact factor: 23.059

5.  Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT?

Authors:  Neeraj Narula; Laurent Peyrin-Biroulet; Jean-Frederic Colombel
Journal:  Gastroenterology       Date:  2014-01-24       Impact factor: 22.682

6.  A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.

Authors:  Elaheh Vahabnezhad; Shervin Rabizadeh; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

Review 7.  Methotrexate for induction of remission in refractory Crohn's disease.

Authors:  John W D McDonald; Yongjun Wang; David J Tsoulis; John K MacDonald; Brian G Feagan
Journal:  Cochrane Database Syst Rev       Date:  2014-08-06

8.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

9.  Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.

Authors:  Ruben J Colman; David T Rubin
Journal:  J Crohns Colitis       Date:  2015-01-23       Impact factor: 10.020

10.  Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.

Authors:  Michael H Schiff; Jonathan S Jaffe; Bruce Freundlich
Journal:  Ann Rheum Dis       Date:  2014-04-12       Impact factor: 19.103
View more
  5 in total

Review 1.  Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers.

Authors:  Hans H Herfarth; Susan Jackson; Barbara G Schliebe; Christopher Martin; Anastasia Ivanova; Kristen Anton; Robert S Sandler; Millie D Long; Kim L Isaacs; Mark T Osterman; Bruce E Sands; Peter D Higgins; James D Lewis
Journal:  Inflamm Bowel Dis       Date:  2017-01       Impact factor: 5.325

2.  Analysis of the Therapeutic Effect of Changyanning on Intestinal Flora in Inflammatory Bowel Disease.

Authors:  Xinyu Hu; Fuyuan Yang
Journal:  Contrast Media Mol Imaging       Date:  2022-06-22       Impact factor: 3.009

3.  Protective effects of apigenin on altered lipid peroxidation, inflammation, and antioxidant factors in methotrexate-induced hepatotoxicity.

Authors:  Mehdi Goudarzi; Mojtaba Kalantar; Elahe Sadeghi; Mojtaba Haghi Karamallah; Hadi Kalantar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-15       Impact factor: 3.000

Review 4.  Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology.

Authors:  Nikoleta Zioga; Dionysios Kogias; Vasiliki Lampropoulou; Nikolaos Kafalis; Charalampos Papagoras
Journal:  Mediterr J Rheumatol       Date:  2022-04-15

5.  The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients.

Authors:  Chanchai Traivaree; Napakjira Likasitthananon; Chalinee Monsereenusorn; Piya Rujkijyanont
Journal:  Cancer Manag Res       Date:  2018-10-10       Impact factor: 3.989
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.